NCT04419025

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 165 (actual)
• Sponsor: Cambridge Health Alliance · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

Detailed description

After being informed of the study and potential risks and benefits, patients meeting eligibility requirements will be randomized to receive oral N-acetylcysteine (NAC) as follows: Inpatients: * N-acetylcystine (NAC) 25 mg/kg PO (rounded up to the nearest 600 mg) q4hrs until discharge * N-acetylcysteine (NAC) 1200 mg PO BID x 1 week post-discharge Outpatients: \- N-acetylcysteine (NAC) 2400 mg PO x 1 then 1200 mg PO BID x 2 weeks

Conditions

• COVID
• Sars-CoV2
• SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
• Oxidative Stress

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	Oral formulation: 600 mg capsules of N-acetylcysteine

Timeline

• Start date: 2020-09-23
• Primary completion: 2021-05-14
• Completion: 2021-05-14
• First posted: 2020-06-05
• Last updated: 2021-05-28

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study